Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Pharmaceutical Design|October 2, 2014
Strategies for skeletal muscle targeting in drug discoveryDavid C Ebner, Peter Bialek, Ayman F El-Kattan, et al.
Current Topics in Medicinal Chemistry|April 13, 2013
Intestinal targeting of drugs: rational design approaches and challengesKevin J Filipski, Manthena V Varma, Ayman F El-Kattan, et al.
Molecular Pharmaceutics|October 28, 2017
Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623Claire L McEvoy, Natalie L Trevaskis, Orlagh M Feeney, et al.
Current Drug Metabolism|December 30, 2010
Targeting intestinal transporters for optimizing oral drug absorptionManthena V Varma, Catherine M Ambler, Mohammad Ullah, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|August 26, 2014
In vitro-in vivo evaluation of lipid based formulations of the CETP inhibitors CP-529,414 (torcetrapib) and CP-532,623Claire L McEvoy, Natalie L Trevaskis, Glenn A Edwards, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|January 2, 2014
Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubilityAmit S Kalgutkar, Kosea S Frederick, Heather L Hatch, et al.
Bioorganic & Medicinal Chemistry|April 8, 2020
Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.
Journal of Medicinal Chemistry|August 17, 2018
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.
Journal of Medicinal Chemistry|May 13, 2017
Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug DesignKatherine L Lee, Catherine M Ambler, David R Anderson, et al.
Pageof 1